Broad vaccine protection against Neisseria meningitidis using factor H binding protein

Jamie Findlow*, Christopher D. Bayliss, Peter T. Beernink, Raymond Borrow, Paul Liberator, Paul Balmer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Neisseria meningitidis, the causative agent of invasive meningococcal disease (IMD), is classified into different serogroups defined by their polysaccharide capsules. Meningococcal serogroups A, B, C, W, and Y are responsible for most IMD cases, with serogroup B (MenB) causing a substantial percentage of IMD cases in many regions. Vaccines using capsular polysaccharides conjugated to carrier proteins have been successfully developed for serogroups A, C, W, and Y. However, because the MenB capsular polysaccharide is poorly immunogenic, MenB vaccine development has focused on alternative antigens. The 2 currently available MenB vaccines (MenB-4C and MenB-FHbp) both include factor H binding protein (FHbp), a surface-exposed protein harboured by nearly all meningococcal isolates that is important for survival of the bacteria in human blood. MenB-4C contains a nonlipidated FHbp from subfamily B in addition to other antigens, including Neisserial Heparin Binding Antigen, Neisserial adhesin A, and outer membrane vesicles, whereas MenB-FHbp contains a lipidated FHbp from each subfamily (A and B). FHbp is highly immunogenic and a main target of bactericidal activity of antibodies elicited by both licensed MenB vaccines. FHbp is also an important vaccine component, in contrast to some other meningococcal antigens that may have limited cross-protection across strains, as FHbp-specific antibodies can provide broad cross-protection within each subfamily. Limited cross-protection between subfamilies necessitates the inclusion of FHbp variants from both subfamilies to achieve broad FHbp-based vaccine coverage. Additionally, immune responses to the lipidated form of FHbp have a superior cross-reactive profile to those elicited by the nonlipidated form. Taken together, the inclusion of lipidated FHbp variants from both FHbp subfamilies is expected to provide broad protection against the diverse disease-causing meningococcal strains expressing a wide range of FHbp sequence variants. This review describes the development of vaccines for MenB disease prevention, with a focus on the FHbp antigen.

Original languageEnglish
Pages (from-to)7716-7727
Number of pages12
Issue number49
Publication statusPublished - 17 Nov 2020

Bibliographical note

Funding Information:
This work was supported by Pfizer Inc. Editorial/medical writing support was provided by Judith Kandel, PhD, of ICON plc (North Wales, PA, USA), and was funded by Pfizer Inc. This publication made use of the Neisseria Multi Locus Sequence Typing website ( sited at the University of Oxford [108] ; the development of this site has been funded by the Wellcome Trust and European Union . This publication also made use of the Meningitis Research Foundation Meningococcus Genome Library ( developed by Public Health England, the Wellcome Trust Sanger Institute, and the University of Oxford as a collaboration; this project is funded by Meningitis Research Foundation.

Publisher Copyright:
© 2020


  • Factor H binding protein
  • Immune selection
  • Meningococcal serogroup B vaccine
  • Neisseria meningitidis


Dive into the research topics of 'Broad vaccine protection against Neisseria meningitidis using factor H binding protein'. Together they form a unique fingerprint.

Cite this